Psyence Biomedical Ltd. Warrant
PBMWW
NASDAQ Global Market0.04
USD
+0.01
- -
CIK
0001985062
ISIN
CA74449F1181
CUSIP
74449F118
Return %
Stock
S&P500
1Y
93.88
26.53
3Y
-16.48
76.60
5Y
-16.48
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Jody Aufrichtig
- Full Time Employees
- 12
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 121 Richmond Street West Toronto ON Canada M5H2K1
- IPO Date
- Jan 26, 2024
- CIK
- 0001985062
- Website
- psyencebiomed.com
- Similar Companies
- Business
- Psyence Biomedical Ltd. is a life science biotechnology company specializing in the development of botanical psilocybin-based psychedelic medicines for mental health, with a primary focus on treating anxiety, depression, and psychosocial distress in palliative care patients. The company manufactures natural psilocybin products cultivated at its federally licensed facility in Southern Africa and develops encapsulated, standardized pharmaceutical forms of these compounds for clinical use. Its product pipeline includes nature-derived psychedelic therapeutics, including psilocybin and ibogaine, targeting mental health disorders within oncology and life-limiting illness contexts. Psyence's clinical operations encompass Phase IIb trials evaluating a 25mg natural psilocybin formulation combined with proprietary psychotherapy for Adjustment Disorder in palliative care, with trials initiated in Australia and patient enrollment underway as of 2025. Recent major changes include a $3.5 million follow-on investment to deepen its strategic partnership and increase equity in PsyLabs, a key supplier of GMP-grade psychedelic active pharmaceutical ingredients (APIs), which secures Psyence's supply chain for natural psychedelic compounds including psilocybin and ibogaine. The company also completed the acquisition of Psyence Group's stake in PsyLabs via a debt-for-equity swap, enhancing vertical integration in developing psychedelic-based, regulatory-approved therapeutics. This strategic move supports Expand its leadership in psychedelic therapeutics by improving supply visibility, procurement risk mitigation, and product pipeline expansion. Psyence also signed a global ibogaine supply agreement to support the development of next-generation psychedelic medicines. Founded in 2017 and headquartered in Canada, Psyence Biomedical operates internationally with key clinical and production facilities in Southern Africa and Australia. The company is publicly traded on Nasdaq under the ticker symbol PBM and targets the pharmaceutical, biotechnology, and mental health sectors, focusing on underserved patient populations requiring innovative mental health treatments in palliative care. Its work is physician-led and evidence-based, blending natural psychedelics with scientific research to develop FDA-approvable, nature-derived medicines for neurological and psychological conditions. Psyence Biomedical's operations include cultivation, GMP manufacturing, clinical development, and global distribution of psychedelic therapeutics. The company maintains compliance with high safety and quality standards through its partnership with PsyLabs, which operates an ISO 22000-certified facility audited by the British Standards Institution. This partnership enables the company to scale production of premium, sustainable psychedelic compounds for advancing its clinical pipeline and commercial opportunities. Overall, Psyence Biomedical Ltd. functions as a vertically integrated, mission-driven biopharmaceutical company pioneering the clinical and commercial development of natural psychedelic medicines, with recent strategic investments and acquisitions strengthening its position in the emerging psychedelic therapeutics market globally.